Choudhary, SunilGupta, NehaVerma, Chandra PrakashDas, AvipsaAggarwal, Lalit MohanTewari, MallikaMandal, AbhijitAsthana, Anupam Kumar2025-01-302025-01-3020219731482https://dl.bhu.ac.in/ir/handle/123456789/24852Purpose: The study was done to evaluate the role of adjuvant therapy in curatively resected Stage II and III gallbladder carcinoma (GBC). Materials and Methods: This was a retrospective analysis of patients of GBC registered between 2008 and 2017 in outpatient department of a tertiary cancer hospital in India. Patients who had any of the following adjuvant treatment after radical surgery: (a) external beam radiotherapy (RT) alone, (b) chemotherapy (CT) alone, and (c) RT with CT (CRT) were considered for the study. Results: A total of fifty patients could meet the selection criteria. It was seen that seven patients were treated with RT, 20 with CT, and 23 with CRT. Median follow-up for patients who were alive was 26.7 months. Nineteen patients had locoregional failure while eight had distant failure. Patients treated with CRT had a significantly better mean overall survival compared to those treated with RT or CT (44.0 months, 12.5 months, and 15.1 months, respectively; P = 0.003). Similarly, mean disease-free survival was superior in CRT arm compared to RT and CT arms (43.6 months, 9.6 months, and 12.4 months, respectively; P = 0.002). Conclusions: Adjuvant CRT had better survival outcome compared to patients treated with either RT or CT with Stage II and III disease after curative cholecystectomy. � 2020 Journal of Cancer Research and Therapeutics.Adjuvant chemotherapyAdjuvant radiotherapyCholecystectomyCombined modality therapyGallbladder cancerArticlehttps://doi.org/10.4103/jcrt.JCRT_550_19